^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MV-NIS

    i
    Other names: MV-NIS, MVNIS, MV NIS, sodium iodide simporter measles virus
    Associations

    News

    Trials
    Company:
    Vyriad
    Drug class:
    Immunostimulant, Cell death stimulant
    Related drugs:
    Associations

    News

    Trials
    16d
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2025 --> Sep 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    3ms
    MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer (clinicaltrials.gov)
    P2, N=17, Terminated, Mayo Clinic | N=66 --> 17 | Active, not recruiting --> Terminated | Active, not recruiting --> Terminated; poor accrual
    Enrollment change • Trial termination • Platinum resistant
    |
    Avastin (bevacizumab) • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • MV-NIS
    12ms
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Mayo Clinic | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Mar 2024
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    1year
    MC1372: Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery (clinicaltrials.gov)
    P1, N=9, Completed, Mayo Clinic | Recruiting --> Completed | N=30 --> 9 | Trial completion date: Sep 2024 --> Apr 2024 | Trial primary completion date: Sep 2024 --> Apr 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Surgery
    |
    MV-NIS
    over1year
    Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures. (PubMed, EBioMedicine)
    Considering the heterogeneity of PDAC and the complexity of biological therapies such as OVs, no single biomarker can explain the spectrum of response patterns. For selection of a particular OV, PDAC molecular subtype, ISG expression as well as activation of distinct signaling and metabolic pathways should be considered. Combination therapies can overcome resistance in specific constellations. Overall, oncolytic virotherapy is a viable treatment option for PDAC, which warrants further development. This study highlights the need for personalised treatment in OVT. By providing all primary data, this study provides a rich source and guidance for ongoing developments.
    Journal • Oncolytic virus • IO biomarker
    |
    LGALS1 (Galectin 1) • CGAS (Cyclic GMP-AMP Synthase)
    |
    Imlygic (talimogene laherparepvec) • MV-NIS • ParvOryx (parvovirus H-1)
    over1year
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=34, Active, not recruiting, Mayo Clinic | Recruiting --> Active, not recruiting | N=57 --> 34
    Enrollment closed • Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    almost2years
    MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    2years
    Oncolytic virotherapies for pediatric tumors. (PubMed, Expert Opin Biol Ther)
    We reviewed seven virus types that have been investigated in past or ongoing pediatric tumor clinical trials: adenovirus (AdV-tk, Celyvir, DNX-2401, VCN-01, Ad-TD-nsIL-12), herpes simplex virus (G207, HSV-1716), vaccinia (JX-594), reovirus (pelareorep), poliovirus (PVSRIPO), measles virus (MV-NIS), and Senecavirus A (SVV-001). However, the antitumor effects of OVT remain variable depending on tumor type and viral agent used. Although the widespread adoption of OVT faces many challenges, we are optimistic that OVT will play an important role alongside standard chemotherapy and radiotherapy for the treatment of malignant pediatric solid tumors in the future.
    Review • Journal • Oncolytic virus
    |
    ProstAtak (aglatimagene besadenovec) • Reolysin (pelareorep) • tasadenoturev (DNX-2401) • HSV G207 • MV-NIS • Pexa-Vec (pexastimogene devacirepvec) • SVV-001 • Seprehvir (HSV1716) • zabilugene almadenorepvec (VCN-01)
    over2years
    MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer (clinicaltrials.gov)
    P1/2, N=57, Recruiting, Mayo Clinic | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule)
    |
    MV-NIS
    over2years
    Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy (clinicaltrials.gov)
    P1, N=8, Completed, Vyriad, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    cisplatin • MV-NIS
    over2years
    Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT (clinicaltrials.gov)
    P1, N=34, Completed, Sabine Mueller, MD, PhD | Recruiting --> Completed | Trial completion date: May 2024 --> May 2023 | Trial primary completion date: Dec 2023 --> May 2023
    Trial completion • Trial completion date • Trial primary completion date
    |
    CD4 (CD4 Molecule)
    |
    MV-NIS
    over2years
    Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Vyriad, Inc. | Recruiting --> Active, not recruiting | N=16 --> 8 | Trial completion date: Dec 2022 --> May 2023 | Trial primary completion date: Apr 2022 --> May 2023
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • MV-NIS